Biodel Successfully Defends Ultra-Rapid-Acting Insulin

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biodel Successfully Defends Ultra-Rapid-Acting Insulin Formulation Technology in European Patent Office Opposition Proceedings

DANBURY, CT --(Marketwired - November 18, 2014) - Biodel Inc. ( NASDAQ : BIOD ) announced that it has successfully defended oppositions to two of its granted European patents for its ultra-rapid-acting insulin formulations, EP 2 319 500 and EP 2 106 790. A third party opposed Biodel's patents in July 2013, but the Opposition Division at the European Patent Office (EPO) recently ruled in favor of the validity of Biodel's patents. The EPO tribunal ruled that all claims of both patents are novel and inventive. Biodel therefore retains all of its patent claims as originally granted.

Biodel's proprietary combination of excipients, when formulated with recombinant human insulin or rapid-acting insulin analogs, alters the pharmacokinetic and pharmacodynamic profiles of the insulin such that it is absorbed more rapidly than current marketed comparators when administered to patients. A key feature of Biodel's formulation technology is that it allows the insulin to disassociate from the six molecule, or hexameric, form to the single molecule form and inhibits re-association to the hexameric form. Biodel believes its ultra-rapid-acting insulin formulations may be more therapeutically effective than many commercially available insulin products.

Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "We were confident that the claims of our two patents were valid and are pleased that the EPO has ruled in our favor. This outcome further validates the strength of Biodel's patent portfolio and the benefits that may be afforded to potential licensees."

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at www.biodel.com . 

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for Biodel's product candidates, potential timing, design and outcomes of clinical trials and Biodel's ability to develop and commercialize its product candidates. Forward-looking statements represent Biodel's management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding Biodel's strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Biodel's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the progress, timing or success of Biodel's research and development and clinical programs for Biodel's product candidates; Biodel's ability to conduct the development work necessary to finalize the formulation and design of Biodel's dual-chamber glucagon rescue product candidate, as well as the preclinical studies, clinical trials and manufacturing activities necessary to support the filing of a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, for that product candidate; Biodel's ability to engage a strategic partner in the further development of Biodel's prandial ultra-rapid-acting insulin formulations, including BIOD-531, which uses regular human insulin, or RHI, as the active pharmaceutical ingredient, and Biodel's insulin analog-based formulations; the success of Biodel's formulation development work to improve the stability of Biodel's newer ultra-rapid-acting insulin analog-based formulations while maintaining the pharmacokinetic and injection site toleration characteristics associated with earlier formulations; the results of Biodel's real-time stability programs for Biodel's RHI-, insulin analog- and glucagon-based product candidates, including the reproducibility of earlier, smaller scale, stability studies and Biodel's ability to accurately project long term stability on the basis of accelerated testing; Biodel's ability to accurately anticipate technical challenges that the company may face in the development of Biodel's ultra-rapid-acting RHI- and insulin analog-based product candidates or Biodel's glucagon rescue product candidates; Biodel's ability to secure approval by the FDA for Biodel's product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act; Biodel's ability to enter into collaboration arrangements for the commercialization of Biodel's product candidates and the success or failure of any such collaborations into which the company enters, or Biodel's ability to commercialize its product candidates on its own; Biodel's ability to enforce Biodel's patents for Biodel's product candidates and Biodel's ability to secure additional patents for Biodel's product candidates; and other factors identified in our most recent report on Form 10-Q for the quarter ended December 31, 2013. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

CONTACT: John Graziano +1-646-378-2942

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 91

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 26

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 43

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 101

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 44

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 20

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 13

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 114

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

CSX Corporation Teams Up for Q1 Earnings Conference Call

Updated Category News Views 131

CSX Corporation's Upcoming First Quarter Earnings Release CSX Corporation (NASDAQ: CSX) is excited to announce its first-quarter earnings release slated for a date following the market close. This pivotal moment will take place on a Wednesday, with management inviting participants to join their insightful conference call. Details of the Earnings Call A live webcast and...

Continue Reading
Innovative ReWalk 7 Exoskeleton Now Available for All Users

Updated Category News Views 345

The Launch of ReWalk 7 Personal Exoskeleton Lifeward Ltd., known for its groundbreaking innovations in medical technology, has recently unveiled its seventh generation of personal exoskeletons, the ReWalk 7. This next-generation device is now available throughout the United States, primarily aiming to benefit individuals with spinal cord injuries (SCI). This remarkable...

Continue Reading
Eve's Certification Progress Marks Aviation Milestone

Updated Category News Views 51

Certification: A New Lease on Air Mobility Folks, the air mobility future is taking one giant leap forward, and Eve Air Mobility is right at the helm. With Brazil’s aviation authority spearheading a consultation for updated airworthiness criteria and Eve stepping up for European certification, these advancements aren't just footnotes—they're headlines. NYSE:EVEX has...

Continue Reading
Exciting Launch of Lofthill Residences: A Premier Investment Hub

Updated Category News Views 164

Lofthill Residences: A Fresh Investment Opportunity in Kuala Lumpur The real estate market in Kuala Lumpur has taken an exciting turn with the introduction of Lofthill Residences, a groundbreaking initiative by TRE Towers and the Armani Group. Conveniently located near the vibrant KLCC and just a short walk from the Raja Uda MRT station, this development stands out as a...

Continue Reading
Exclaimer Welcomes Rob Singer as CEO to Propel Growth

Updated Category News Views 385

Exclaimer Welcomes New Leadership for Future Growth Exclaimer, a leader in email signature management, has announced the appointment of Rob Singer as its new CEO. This comes at a key moment for the company, which has recently doubled its annual revenue and is set to expand its presence with new offices opening soon. Experience and Vision Matter Rob Singer comes to...

Continue Reading